Atrial Fibrillation
Friday, November 22nd, 2013
Med Care Res Rev: November 19, 2013 Despite evidence-based guidelines, oral anticoagulation therapy (OAT) initiation is low among incident atrial fibrillation (AF) patients. Patient-centered medical homes (PCMHs) may increase access, quality, and value through coordinating care. As such, PCMHs hold potential for improving OAT initiation among AF patients. We estimated the effect of receiving care in […]
Atrial Fibrillation
Friday, November 22nd, 2013
HealthDay Reporter: 11/18/18 Atrial fibrillation can lead to dangerous heart complications MONDAY, Nov. 18, 2013 (HealthDay News) — Hospitalizations for the most common form of irregular heartbeat nearly doubled between 1998 and 2010, and are expected to continue to soar during the current decade, researchers say. Ultimately, hospital treatment of atrial fibrillation could cost the United […]
Atrial Fibrillation
Friday, November 22nd, 2013
CIRCULATIONAHA: November 18, 2013 Background—Electrical, structural, and Ca2+-handling remodeling contribute to the perpetuation/progression of atrial fibrillation (AF). Recent evidence has suggested a role for spontaneous sarcoplasmic reticulum Ca2+-release events in long-standing persistent AF, but the occurrence and mechanisms of sarcoplasmic reticulum Ca2+-release events in paroxysmal AF (pAF) are unknown. Method and Results—Right-atrial appendages from control sinus […]
Atrial Fibrillation
Friday, November 22nd, 2013
Healthday: 11/18/13 Damage to blood vessels of the retinas and kidneys tied to higher risk for atrial fibrillation, study found MONDAY, Nov. 18, 2013 (HealthDay News) — Damage to the blood vessels of the eyes or kidneys might help identify people who are at raised risk for a common type of heart-rhythm disorder, a new study […]
Atrial Fibrillation
Friday, November 22nd, 2013
AHA: 11/15/13 Background—Adenosine (ADO) can unmask dormant pulmonary vein (PV) conduction following PV isolation. ADO can also induce ectopy in electrically silent PVs following isolation, possibly via activation of autonomic triggers. We sought to identify the implications of ADO-induced PV ectopy for atrial fibrillation (AF) recurrence following PV isolation. Methods and Results—A total of 152 patients […]
Clinical Trials
Friday, November 22nd, 2013
Medpagetoday: 11/21/13 DALLAS — A pacemaker set to pace only when and where needed improved patient outcomes, particularly the risk of permanent atrial fibrillation, a trial showed. The sophisticated predictive, right-ventricle sparing programming was associated with a 26% reduction in risk of death from any cause, cardiovascular-related hospitalization, or permanent afib compared with standard dual-chamber pacing […]
Clinical Trials
Friday, November 22nd, 2013
JAMA: November 20, 2013 Importance Obesity is a risk factor for atrial fibrillation. Whether weight reduction and cardiometabolic risk factor management can reduce the burden of atrial fibrillation is not known. Objective To determine the effect of weight reduction and management of cardiometabolic risk factors on atrial fibrillation burden and cardiac structure. Design, Setting, and Patients Single-center, partially blinded, randomized […]
Clinical Trials
Friday, November 22nd, 2013
Medpagetoday: Nov 20, 2013 DALLAS — Ablating the atrial chamber substrate for prevention of paroxysmalatrial fibrillation appears to be noninferior to the standard method of ablating suspected triggers in the pulmonary veins, researchers reported here. Of 58 patients treated with circumferential pulmonary vein ablation, 40, or 69%, achieved freedom from paroxysmal bouts of atrial fibrillation at 12 […]
Clinical Trials
Friday, November 22nd, 2013
NEJM: 11/19/13 BACKGROUND The clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results. Full Text of Background… METHODS We randomly assigned 1015 patients to receive doses of warfarin during the first 5 days of therapy that were determined according to a […]
Clinical Trials
Friday, November 22nd, 2013
NEJM: 11/19/13 Observational evidence suggests that the use of a genotype-guided dosing algorithm may increase the effectiveness and safety of acenocoumarol and phenprocoumon therapy. Full Text of Background… METHODS We conducted two single-blind, randomized trials comparing a genotype-guided dosing algorithm that included clinical variables and genotyping for CYP2C9 and VKORC1 with a dosing algorithm that included only clinical variables, for […]
